Madrigal Pharmaceuticals (MDGL) Intangibles (2024 - 2026)
Madrigal Pharmaceuticals (MDGL) posted quarterly Intangibles of $7.2 million for Q2 2026, up 58.03% year-over-year from $4.5 million in Q2 2025, and down 1.33% quarter-over-quarter from $7.3 million in Q1 2026.
Madrigal Pharmaceuticals (MDGL) Intangibles (2024 - 2026) Analysis & Trends
Madrigal Pharmaceuticals (MDGL) has reported Intangibles for 3 consecutive years, with $7.2 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Intangibles rose 58.03% year-over-year to $7.2 million; the TTM figure through Jun 2026 stood at $7.2 million (up 58.03% YoY), while the FY2025 annual figure was $7.4 million, up 56.08% from the prior year.
- Intangibles declined to $7.2 million in Q2 2026 per MDGL's latest filing, from $7.3 million in the prior quarter.
- Across five years, Intangibles topped out at $7.5 million in Q3 2025 and bottomed at $4.5 million in Q2 2025.
- Historically, Intangibles has averaged $5.8 million across 3 years, with a median of $5.0 million in 2024.
- Annual changes were most pronounced in 2025 — Intangibles slipped 7.37% — and 2026, when it jumped 58.03%.
- Madrigal Pharmaceuticals' Intangibles stood at $4.7 million in 2024, then jumped by 56.08% to $7.4 million in 2025, then fell by 2.63% to $7.2 million in 2026.
- Business Quant data shows MDGL's Intangibles at $7.2 million in Q2 2026, $7.3 million in Q1 2026, and $7.4 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 266.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 63.28 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 60.96 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 93.49 Mn |
| 10 | Madrigal Pharmaceuticals | 14.79 Bn | 13.95 Bn | - | 7.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.19 Mn |
| Mar 31, 2026 | 7.28 Mn |
| Dec 31, 2025 | 7.38 Mn |
| Sep 30, 2025 | 7.48 Mn |
| Jun 30, 2025 | 4.55 Mn |
| Mar 31, 2025 | 4.64 Mn |
| Dec 31, 2024 | 4.73 Mn |
| Sep 30, 2024 | 4.82 Mn |
| Jun 30, 2024 | 4.91 Mn |
| Mar 31, 2024 | 5.00 Mn |